International Medical Journal, Vol. 22., Iss. 4, 2016, P. 5−12.
CONGRESS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ROME, 2016): RESULTS OF THE MOST IMPORTANT CLINICAL TRIALS
Kuban State Medical University (Ministry of Health of Russian Federation), Krasnodar, Russian Federation
Annual congress of the European Society of Cardiology was held on August 27−31, 2016 in Rome, where 4 new texts of Clinical Guidelines for the diagnosis and treatment of acute and chronic heart failure, prevention of cardiovascular disease in clinical practice, treatment of dyslipidemia and atrial fibrillation as well as a consensus document on cardiovascular toxicity in cancer treatment were presented. The greatest interest was aroused by the results the newly presents 28 specially selected clinical trials, which are traditionally presented at Hot Line sessions. Hot Line I, Heart failure and Innovative Approaches, stressed that the predictive efficacy of preventive use of implantable cardioverter−defibrillator was proved only in patients with systolic chronic heart failure of ischemic origin. Hot Line II, Preventive Strategies 1, considered preventive strategies in patients after percutaneous coronary intervention. In particular, the need for individualization of antiplatelet therapy was emphasized, the hypothesis about the possibility of limiting the size of myocardial infarction with a combination of N−acetyl cysteine and nitroglycerin was studied. Hot Line III, Prevention and Lipids, noted that after acute coronary syndrome high−intensity statin therapy was recommended. Hot Line IV, Coronary Artery Disease and Imaging presented the first randomized study that assessed the value of optical coherence tomography, compared the findings of positron emission tomography, single photon emission computed tomography, coronary computed tomography. Hot Line V, Coronary Artery Disease and Stenting, presented the largest randomized study of modern drug−coated stents. Hot Line VI, Preventive Strategies 2, demonstrated the results of testing of drugs for alternative treatment of patients with non−valvular atrial fibrillation undergoing electrical cardioversion, andexanet alpha, used to control major bleeding associated with administration of factor Xa inhibitors and estimated modified algorithm of pulmonary thromboembolism diagnosis.
Key words: cardiovascular diseases, clinical trials, Hot Line sessions.